

Balaxi Pharmaceuticals Limited

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No C/1, G Block, BKC
Bandra (E), Mumbai-400051

17th July, 2021

Stock Code: BALAXI

Sub: Un-audited Standalone and Consolidated Financial Results for the 1st quarter 30th June, 2021

Dear Sir/Madam,

With reference to the above subject and pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, please find attached herewith Unaudited Standalone and Consolidated Financial Results along with the Limited Review Report for the 1st quarter ended 30th June, 2021.

These financial results were approved by the Board of Directors of the Company at their meeting held on 17th July, 2021.

The above information is available at the website of the Company at www.balaxipharma.in

This is for your information and record.

Thanking You

Yours Faithfully,
For **Balaxi Pharmaceuticals Limited**


Chinta Shalini
Company Secretary



Registered Office:

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

(Formerly known as Balaxi Ventures Limited)

Balaxi Pharmaceuticals Limited

2nd Floor, MAPS Towers, Plot no. 409, Road no. 81, Jubilee Hills, Phase III, Hyderabad-500096, Telangana
CIN:L25191TG1942PLC121598

Unaudited Standalone Financial Results for the quarter ended 30th June, 2021


Particulars	(Rs. in Lakhs)			
	Quarter Ended		Year ended	
	30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
Income				
Revenue from operations	2,918.04	2,259.71	2,115.27	8,687.11
Other income	99.19	4.31	146.76	180.98
Total Income	3,017.23	2,264.02	2,262.03	8,868.09
Expenses				
Cost of materials consumed	2,267.55	1,652.91	1,543.30	6,332.84
Employee benefit expense	60.31	56.73	39.67	194.83
Finance cost	0.25	0.40	-	1.31
Depreciation and amortisation expense	2.63	2.42	0.71	8.75
Administrative expenses	93.08	91.01	49.33	270.69
Total Expenses	2,423.82	1,803.47	1,633.01	6,808.42
Profit/(loss) before tax and other comprehensive income	593.41	460.55	629.02	2,059.67
Tax expenses				
Current tax	150.23	144.55	157.83	545.96
Deferred tax	(0.07)	0.05	0.50	0.37
Net Profit/(loss) for the period	443.25	315.95	470.69	1,513.34
Other comprehensive income				
A (i) Items that will not be reclassified to profit or loss in subsequent period	-	-		-
Re-measured gains on defined benefit plans	-	-		-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-		-
B (i) Items that will be reclassified to profit or loss	-	-		-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-		-
Total comprehensive income for the year	443.25	315.95	470.69	1,513.34
Paid up equity share capital - Face value of Rs.10 each	1,000.00	1,000.00	1,000.00	1,000.00
Other Equity				
Earnings Per Share (EPS) (EPS for the quarter is not annualised)				
-Basic (Amount in Rs.)	4.43	3.16	4.71	15.13
-Diluted (Amount in Rs.)	4.43	3.16	4.71	15.13

Notes :

- The Unaudited Standalone Financial Results for the quarter ended 30th June, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 17th July, 2021. The Standalone Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.
- Previous period figures have been regrouped, re-arranged and re-classified wherever necessary to conform to current period's classification.
- The operating segment of the Group is identified as "Specialized Wholesale" as the Management reviews business performance at an overall level as one segment. Therefore, the disclosure as per Regulation 33 (1)(e) read with Clause L of Schedule IV of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company.

For and on behalf of Board of Directors,


Ashish Maheshwari
 Managing Director
 DIN: 01575984



Place: Hyderabad
Date: 17th July, 2021



P.MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel (91-40) 2332 6666, 2331 2554
2339 3967 2332 1470
Fax (91-40) 2339 2474
E-mail pmurali.co@gmail.com
info@pmurali.com
Website . www.pmurali.com


Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review report to
The Board of Directors
Balaxi Pharmaceuticals limited

We have reviewed the accompanying statement of unaudited standalone financial results of **BALAXI PHARMACEUTICALS LIMITED** (Formerly Known as Balaxi Ventures Limited) (the "Company") for the quarter ended June 30, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ('Ind AS 34,') prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





P.MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082 INDIA

Tel : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants
FRN: 007257S



A. Krishna Rao

Partner

M.No. 020085

UDIN: 21020085AAAAARY6869

Place: Hyderabad

Date: 17-07-2021.

